Akebia Therapeutics (NASDAQ:AKBA – Free Report) had its target price boosted by HC Wainwright from $6.00 to $7.50 in a research note published on Monday, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Akebia Therapeutics’ Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.04) EPS, FY2024 earnings at ($0.22) EPS, Q1 2025 earnings at ($0.14) EPS, Q2 2025 earnings at ($0.13) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.12) EPS, FY2027 earnings at $0.40 EPS and FY2028 earnings at $1.29 EPS.
Separately, StockNews.com downgraded Akebia Therapeutics from a buy rating to a hold rating in a research report on Monday, April 29th.
Check Out Our Latest Report on Akebia Therapeutics
Akebia Therapeutics Price Performance
Akebia Therapeutics (NASDAQ:AKBA – Get Free Report) last released its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The firm had revenue of $43.65 million during the quarter, compared to analysts’ expectations of $45.61 million. During the same period in the previous year, the firm posted ($0.06) earnings per share. On average, analysts anticipate that Akebia Therapeutics will post -0.28 EPS for the current year.
Hedge Funds Weigh In On Akebia Therapeutics
Hedge funds have recently made changes to their positions in the stock. Raymond James & Associates boosted its holdings in Akebia Therapeutics by 48.0% in the fourth quarter. Raymond James & Associates now owns 29,917 shares of the biopharmaceutical company’s stock valued at $37,000 after acquiring an additional 9,696 shares during the last quarter. Sapient Capital LLC purchased a new position in shares of Akebia Therapeutics in the 4th quarter worth about $248,000. Mackenzie Financial Corp lifted its stake in shares of Akebia Therapeutics by 37.6% in the 4th quarter. Mackenzie Financial Corp now owns 23,159 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 6,330 shares in the last quarter. Archer Investment Corp purchased a new stake in shares of Akebia Therapeutics during the 4th quarter worth about $25,000. Finally, Eagle Wealth Strategies LLC acquired a new stake in Akebia Therapeutics during the 4th quarter worth approximately $25,000. Institutional investors and hedge funds own 33.92% of the company’s stock.
Akebia Therapeutics Company Profile
Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients.
Further Reading
- Five stocks we like better than Akebia Therapeutics
- How to Find Undervalued Stocks
- Brinker International’s Price Dip is an Appetizing Entry Point
- How to Capture the Benefits of Dividend Increases
- 3 Stocks That Could Beat the September Blues
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.